Zobrazeno 1 - 10
of 293
pro vyhledávání: '"Tomoyuki Nagai"'
Autor:
Masashi Kono, Yoriaki Komeda, George Tribonias, Saki Yoshida, Kenji Nomura, Kohei Handa, Tomoyuki Nagai, Satoru Hagiwara, Shunsuke Omoto, Mamoru Takenaka, Naoshi Nishida, Naoko Tsuji, Hiroshi Kashida, Masatoshi Kudo
Publikováno v:
JGH Open, Vol 7, Iss 8, Pp 579-583 (2023)
Abstract Background and Aim Serum leucine‐rich alpha‐2 glycoprotein level has been reported to be a useful biomarker in assessing mucosal healing in patients undergoing biotherapy, where mucosal lesions caused by ulcerative colitis are difficult
Externí odkaz:
https://doaj.org/article/38ca386887804f7ea46a536928e107da
Autor:
Toshiharu Sakurai, Marco A De Velasco, Kazuko Sakai, Tomoyuki Nagai, Hiroki Nishiyama, Kentaro Hashimoto, Hirotsugu Uemura, Hisato Kawakami, Kazuhiko Nakagawa, Hiroyuki Ogata, Kazuto Nishio, Masatoshi Kudo
Publikováno v:
Molecular Oncology, Vol 16, Iss 7, Pp 1493-1507 (2022)
Immune checkpoint inhibitors (ICIs) are widely used to treat various malignancies. Although the gut microbiome is known to influence the efficacy of ICIs on epithelial tumors, the functional interactions between gut taxa and colonic mucosa remain poo
Externí odkaz:
https://doaj.org/article/d953bfb730bd47ca942694545bf5a7ad
Autor:
Toshiharu Sakurai, Hiroki Nishiyama, Tomoyuki Nagai, Susumu Goto, Hiroyuki Ogata, Masatoshi Kudo
Publikováno v:
BMC Gastroenterology, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background Gankyrin (GK) is an oncoprotein which regulates inflammatory responses and its inhibition is considered as a possible anti-inflammatory therapy for inflammatory bowel disease (IBD). Methods In this study, we investigated the role
Externí odkaz:
https://doaj.org/article/b959fdfa8eae4d4c926a564e58ba2d19
Autor:
Kazuko Sakai, Toshiharu Sakurai, Marco A. De Velasco, Tomoyuki Nagai, Takaaki Chikugo, Kazuomi Ueshima, Yurie Kura, Takayuki Takahama, Hidetoshi Hayashi, Kazuhiko Nakagawa, Masatoshi Kudo, Kazuto Nishio
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Immune checkpoint inhibitors (ICIs) have become the standard of care for several cancers. However, ICI therapy has also been associated with various immune-related adverse events (irAEs). Clinical manifestations of immune-related colitis resemble tho
Externí odkaz:
https://doaj.org/article/6e88ea98895e4ac398d97856814274aa
Autor:
Masumi Ishibashi, Hitoshi Niikura, Motoko Ishida, Noriyuki Iwama, Hirohito Metoki, Shogo Shigeta, Tomoyuki Nagai, Hideki Tokunaga, Muneaki Shimada, Nobuo Yaegashi
Publikováno v:
Tohoku Journal of Experimental Medicine; May2024, Vol. 263 Issue 1, p1-9, 9p
Autor:
Shinichi Togami, Akihide Tanimoto, Shintaro Yanazume, Hideki Tokunaga, Tomoyuki Nagai, Mika Watanabe, Hideaki Yahata, Kazuo Asanoma, Hidetaka Yamamoto, Tomohito Tanaka, Masahide Ohmichi, Takashi Yamada, Yukiharu Todo, Ryutaro Yamada, Hidenori Kato, Wataru Yamagami, Kenta Masuda, Miho Kawaida, Hitoshi Niikura, Takuya Moriya, Hiroaki Kobayashi
Publikováno v:
Gynecologic Oncology. 170:70-76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4092ab6a273fec87f9c564037d51849e
https://doi.org/10.1016/j.ygyno.2022.12.016
https://doi.org/10.1016/j.ygyno.2022.12.016
Autor:
Shogo Shigeta, Muneaki Shimada, Keita Tsuji, Tomoyuki Nagai, Yasuhito Tanase, Koji Matsuo, Shoji Kamiura, Takashi Iwata, Harushige Yokota, Mikio Mikami
Publikováno v:
International Journal of Clinical Oncology. 27:1507-1515
Adjuvant therapy is usually considered for surgically treated patients with uterine cervical cancer harboring intermediate risk (IR) factors such as large tumor diameter, stromal invasion to the outer half, and lymphovascular space invasion (LVSI). H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae1dc212a2330ebe9201eb362dba25bd
https://doi.org/10.1007/s10147-022-02198-6
https://doi.org/10.1007/s10147-022-02198-6
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Kazuko Matsumoto, Yoshihiko Fujita, Hideharu Kimura, Keiichi Aomatsu, Daisuke Tamura, Hiroyasu Kaneda, Kanae Kudo, Kazuko Sakai, Kazuyuki Furuta, Tokuzo Arao, Tomoyuki Nagai
Supplementary Figures 1-5 from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ac10c120b3fe794e966f736c11be4e
https://doi.org/10.1158/1535-7163.22483866.v1
https://doi.org/10.1158/1535-7163.22483866.v1
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Yoshihiko Fujita, Marco A. De Velasco, Keiichi Aomatsu, Daisuke Tamura, Kazuko Matsumoto, Hiroyasu Kaneda, Kazuko Sakai, Kazuyuki Furuta, Tomoyuki Nagai, Kaoru Tanaka, Tokuzo Arao, Kanae Kudo
Purpose: BIBF 1120 is a potent, orally available triple angiokinase inhibitor that inhibits VEGF receptors (VEGFR) 1, 2, and 3, fibroblast growth factor receptors, and platelet-derived growth factor receptors. This study examined the antitumor effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::290335ebbb8795f2dc515fa7a390aef8
https://doi.org/10.1158/1078-0432.c.6519036
https://doi.org/10.1158/1078-0432.c.6519036
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Kazuko Matsumoto, Yoshihiko Fujita, Hideharu Kimura, Keiichi Aomatsu, Daisuke Tamura, Hiroyasu Kaneda, Kanae Kudo, Kazuko Sakai, Kazuyuki Furuta, Tokuzo Arao, Tomoyuki Nagai
Supplementary Figure Legends from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e804f6c9095821d1f1710d28769d498
https://doi.org/10.1158/1535-7163.22483869.v1
https://doi.org/10.1158/1535-7163.22483869.v1